

SenzaGen receives SEK 0.65 million order for GARD®skin Dose-Response from one of the world's leading cosmetics companies

Lund, July 9, 2021

SenzaGen has been selected to test ingredients in cosmetics products from one of the world's largest cosmetics companies. Valued at SEK 0.65 million, the project includes SenzaGen's unique GARD™skin Dose-Response assay. The tests will be performed in SenzaGen's GLP-certified laboratory in Lund.

SenzaGen now starts to collaborate with one of the world's leading companies in the beauty and cosmetics market. With GARD™skin Dose-Response, the company wants to determine the dose at which a substance or a mixture in a cosmetic product cause allergy. This may apply, for example, to certain perfumes, preservatives, herbal ingredients, or hair dyes.

"We are very pleased that one of the largest cosmetics companies and top beauty brands chooses to test ingredients with our unique test method GARD™skin Dose-Response and see it as a great recognition of both SenzaGen and GARD™. The collaboration confirms the trust in that the GARD technology is able to identify the dosage at which a substance may induce sensitization, and further demonstrates SenzaGen's strong position in this market segment. It is a verification that GARD™skin Dose-Response meets a need that companies and researchers in the cosmetics industry have expressed for a long time and that we are one of the first companies to fulfil. We look forward to providing data that ensures that the company's products do not contain allergenic substances that may cause problems for consumers around the world", says Axel Sjöblad, CEO of SenzaGen.

The GARD™skin Dose-Response test provides information on the dose at which a substance causes allergy. The test enables companies in industries including cosmetics, pharmaceuticals, and chemicals to identify the highest possible quantity of a chemical that they can include in their products ("the Dose of Departure"). This serves as crucial information for prioritization and decision-making in research and development. The new test is an expanded application domain of GARD™ skin, and it is one of the first of its kind on the market.

Contacts

Axel Sjöblad, CEO, SenzaGen AB

Email: axel.sjoblad@senzagen.com | Mobile: +46 705-35 93 51

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708-20 29 44



About us

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance's allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen's GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[SenzaGen receives SEK 0.65 million order for GARD®skin Dose-Response from one of the world's leading cosmetics companies](#)